ArticleIndian journal of pharmacology2011
Promising molecular targeted therapies in breast cancer.
Article in Indian journal of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 74 citations in OpenAlex.
- A review of nanomaterials from synthetic and natural molecules for prospective breast cancer nanotherapy.Frontiers in pharmacology · 2023Review
- Identification and validation of a prognostic risk model based on caveolin family genes for breastFrontiers in cell and developmental biology · 2022Article
- YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.International journal of molecular sciences · 2021Article
- Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer.Molecular and clinical oncology · 2021Article
- Immunotherapy for Breast Cancer Treatment.Iranian biomedical journal · 2021Article
- Breast cancer therapy affects the expression of antineonatal Nav1.5 antibodies in the serum of patients with breast cancer.Oncology letters · 2021Article
- Exosomal-mediated transfer of OIP5-AS1 enhanced cell chemoresistance to trastuzumab in breast cancer via up-regulating HMGB3 by sponging miR-381-3p.Open medicine (Warsaw, Poland) · 2021Article
- The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer.Molecular medicine (Cambridge, Mass.) · 2018Article
- Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.Integrative cancer therapies · 2018Article
- 'Lnc'-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling.British journal of pharmacology · 2017Review
- Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update.International journal of molecular sciences · 2017Review
- Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting.Seminars in oncology nursing · 2017Review
- Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2017Review
- Regulation of angiogenic factors by the PI3K/Akt pathway in A549 lung cancer cells under hypoxic conditions.Oncology letters · 2017Article
- Targeted therapies in breast cancer: New challenges to fight against resistance.World journal of clinical oncology · 2017Review
- Selective Targeting of the L858R Mutation (EGFR) in Non-Small Cell Lung Cancer: A Mechanism for Advancing Targeted Chemotherapy.Frontiers in oncology · 2017Article
- Article
- An update on the management of breast cancer in Africa.Infectious agents and cancer · 2017Review
- Novel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer.ACS omega · 2016Article
- Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer.International journal of molecular sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
In recent years, there has been a significant improvement in the understanding of molecular events and critical pathways involved in breast cancer. This has led to the identification of novel targets and development of anticancer therapies referred to as targeted therapy. Targeted therapy has high specificity for the molecules involved in key molecular events that are responsible for cancer phenotype such as cell growth, survival, migration, invasion, metastasis, apoptosis, cell-cycle progression, and angiogenesis. Targeted agents that have been approved for breast cancer include trastuzumab and lapatinib, directed against human epidermal growth factor receptor 2 (HER2) and bevacizumab, directed against vascular endothelial growth factor (VEGF). Several other targeted agents currently under evaluation in preclinical and clinical trials include inhibitors of epidermal growth factor receptor (EGFR), dual EGFR and HER2 inhibitors, VEGF/VEGFR inhibitors, and agents that interfere with crucial signaling pathways such as PI3K/AKT/mTOR and RAS/MEK/ERK; agents against other tyrosine kinases such as Src, insulin-like growth factor (IGF)/IGF-receptor (IGFR); agents that promote apoptosis such as Poly ADP ribose polymerase inhibitors; agents that target invasion and metastasis such as matrix metalloproteinases inhibitors and others. In this review, we highlight the most promising targeted agents and their combination with mainstream chemotherapeutic drugs in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.